Patents by Inventor Shwetal V. Mehta

Shwetal V. Mehta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Genetic signature of vulnerability to inhibitors of base excision repair (BER) in cancer
    Patent number: 10227659
    Abstract: The invention relates to the identification of genetic signatures and expression profiles that are a part of the Base Excision Repair (BER) pathway, a major DNA repair pathway that modifies base lesions. In one embodiment, the present invention provides a method of determining responsiveness of treatment by BER inhibitors for malignant glioma by determining the presence of a low level of expression of Apex 1, a low level of expression of Apex 2, and a high level of expression of MPG.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: March 12, 2019
    Assignees: Dignity Health, The Translational Genomics Research Institute
    Inventors: Shwetal V. Mehta, Michael E. Berens, Harshil Dineshkumar Dhruv
  • GENETIC SIGNATURE OF VULNERABILITY TO INHIBITORS OF BASE EXCISION REPAIR (BER) IN CANCER
    Publication number: 20170204472
    Abstract: The invention relates to the identification of genetic signatures and expression profiles that are a part of the Base Excision Repair (BER) pathway, a major DNA repair pathway that modifies base lesions. In one embodiment, the present invention provides a method of determining responsiveness of treatment by BER inhibitors for malignant glioma by determining the presence of a low level of expression of Apex 1, a low level of expression of Apex 2, and a high level of expression of MPG.
    Type: Application
    Filed: March 31, 2017
    Publication date: July 20, 2017
    Applicants: Dignity Health, The Translational Genomics Research Institute
    Inventors: Shwetal V. Mehta, Michael E. Berens, Harshil Dineshkumar Dhruv
  • Genetic signature of vulnerability to inhibitors of base excision repair (BER) in cancer
    Patent number: 9637798
    Abstract: The invention relates to the identification of genetic signatures and expression profiles that are a part of the Base Excision Repair (BER) pathway, a major DNA repair pathway that modifies base lesions. In one embodiment, the present invention provides a method of determining responsiveness of treatment by BER inhibitors for malignant glioma by determining the presence of a low level of expression of Apex 1, a low level of expression of Apex 2, and a high level of expression of MPG.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: May 2, 2017
    Assignees: Dignity Health, The Translational Genomics Research Institute
    Inventors: Shwetal V. Mehta, Michael E. Berens, Harshil Dineshkumar Dhruv
  • GENETIC SIGNATURE OF VULNERABILITY TO INHIBITORS OF BASE EXCISION REPAIR (BER) IN CANCER
    Publication number: 20160102360
    Abstract: The invention relates to the identification of genetic signatures and expression profiles that are a part of the Base Excision Repair (BER) pathway, a major DNA repair pathway that modifies base lesions. In one embodiment, the present invention provides a method of determining responsiveness of treatment by BER inhibitors for malignant glioma by determining the presence of a low level of expression of Apex 1, a low level of expression of Apex 2, and a high level of expression of MPG.
    Type: Application
    Filed: May 21, 2014
    Publication date: April 14, 2016
    Applicants: The Translational Genomics Research Institute, Dignity Health
    Inventors: Shwetal V. Mehta, Michael E. Berens, Harshil Dineshkumar Dhruv